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ABSTRACT
This molecular epidemiological study was designed to determine the antimalarial drug 
resistance pattern, and the genetic diversity of malaria isolates collected from a war-altered 
Federally Administered Tribal Area (FATA), in Pakistan. Clinical isolates were collected 
from Bajaur, Mohmand, Khyber, Orakzai and Kurram agencies of FATA region between 
May 2017 and May 2018, and they underwent DNA extraction and amplification. The 
investigation of gene polymorphisms in drug resistance genes (dhfr, dhps, crt, and mdr1) 
of Plasmodium falciparum and Plasmodium vivax was carried out by pyrosequencing and 
Sanger sequencing, respectively. Out of 679 PCR-confirmed malaria samples, 523 (77%) 
were P.  vivax, 121 (18%) P.  falciparum, and 35 (5%) had mixed-species infections. All 
P. falciparum isolates had pfdhfr double mutants (C59R+S108N), while pfdhfr/pfdhps triple 
mutants (C59R+S108N+A437G) were detected in 11.5% of the samples. About 97.4% 
of P. falciparum isolates contained pfcrt K76T mutation, while pfmdr1 N86Y and Y184F 
mutations were present in 18.2% and 10.2% of the samples. P. vivax pvdhfr S58R mutation 
was present in 24.9% of isolates and the S117N mutation in 36.2%, while no mutation in 
the pvdhps gene was found. Pvmdr1 F1076L mutation was found in nearly all samples, as 
it was observed in 98.9% of isolates. No significant anti-folate and chloroquine resistance 
was observed in P.  vivax; however, mutations associated with antifolate-resistance were 
found, and the chloroquine-resistant gene has been observed in 100% of P.  falciparum 
isolates. Chloroquine and sulphadoxine-pyrimethamine resistance were found to be high in 
P. falciparum and low in P. vivax. Chloroquine could still be used for P. vivax infection but 
need to be tested in vivo, whereas a replacement of the artemisinin combination therapy for 
P. falciparum appears to be justified.
KEYWORDS: Malaria. FATA. Plasmodium falciparum. Plasmodium vivax. Antimalarial 
drug resistance. Pakistan.
INTRODUCTION
Malaria is still a public health concern despite tremendous efforts to control 
and eradicate malaria. About 229 million malaria cases were reported by the World 
Health Organization (WHO) in 2020, with 0.41 million deaths globally1. About 
205 million people in Pakistan live in the malaria-endemic areas, and 0.3 million 
confirmed cases are reported annually. According to the Malarial Control Program, 
Plasmodium vivax corresponds to 84% of all malarial infections, the proportion 
of Plasmodium falciparum is 15%, and mixed-species infections are around 1% 
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(P.  falciparum and P.  vivax). A Federally Administered 
Tribal Area (FATA) of Pakistan has the second-highest 
malaria incidence (23%) in the country, after the Khyber 
Pakhtunkhwa (KPK) province (31%)2. Political instability 
and war against terrorism during the last two decades have 
destroyed the health care system and its infrastructure in 
FATA. Other factors like militancy, Talibanization, Afghan 
refugees, migration of internally displaced people, and 
poor health system setup have ruined all efforts made by 
malaria control programs in this remote, neglected and 
malaria-endemic region3. 
Chloroquine resistance (CQR) has first appeared in 
Thailand in 1957, then spread throughout South and 
Southeast Asia, eventually appearing in Sub-Saharan Africa 
and South America by the 1970s4. CQR in P. falciparum 
was initially documented in Pakistan in the early 1980s, 
and according to a 1997 survey, CQR in the Pakistani 
population ranged from 18% to 62%5. According to a study 
conducted in Punjab province, 34% of CQR was found in 
five districts6. In 2007, the national treatment guidelines for 
P. falciparum were released, contraindicating the use of CQ 
and encouraging the use of artemisinin with sulfadoxine-
pyrimethamine (SP). the artemisinin-based combination 
therapy (ACT)1. SP had been used as a monotherapy to treat 
malaria infections, and it had been also used as a partner 
drug to ACT before 2018. However, according to the WHO 
guidelines, artemether-lumefantrine plus primaquine is 
now the first-line treatment for uncomplicated confirmed 
P. falciparum malaria, while artesunate is indicated for the 
treatment of severe malaria in Pakistan1. 
Single Nucleotide Polymorphisms (SNPs) in P. falciparum 
pfcrt and pfmdr1 genes are well documented molecular 
markers related to the in vitro CQR. Polymorphism at codon 
K76T of the pfcrt7 gene, and N86Y, Y184F, S1034C, N1042D 
and D1246Y in the pfmdr1 gene confer CQR8. SP partner 
drug of ACT targets the P.  falciparum folate metabolism 
pathway in which two enzymes act: dihydrofolate reductase 
(PDHFR) and dihydropteroate synthase (DHPS)9, that 
have been used as molecular related to the in vitro 
drug susceptibility10. In 2018, WHO recommended the 
replacement of the ACT partner drug from SP by lumefantrine 
due to the development of P.  falciparum resistance to SP 
in Pakistan11. Polymorphism in the pfdhdr gene at C50R, 
N51I, C59R, S108N, I164L codons as well as at S436A, 
A437G, K540E, A581G,A613T/S codons in pfdhps genes 
of P.  falciparum have been associated with reduced SP 
susceptibility. Molecular markers of drug resistance against 
SP have been reported in a few studies on blood samples 
representing different Pakistan provinces except for the 
Federally Administered Tribal Area (FATA) in Pakistan12,13. 
In in vitro/in vivo investigations have revealed the artemisinin 
resistance along the Thailand-Cambodia border, in Vietnam, 
Myanmar and other Southeast Asian countries14 but it is still 
an effective antimalarial drug in Pakistan12,15. 
In Southeast Asia, malaria due to P. vivax is prevalent, and 
80% of the malaria burden come from India, Indonesiaand 
Pakistan1. The CQR mutation has been found in 100% of 
samples with P.  falciparum; however, chloroquine plus 
primaquine is the first-line treatment for malaria due to 
P. vivax in Pakistan. SNPs in the pvmdr1 gene have been 
associated with CQR in P.  vivax, and two mutations at 
position Y976F and F1076L have been linked to chloroquine 
amodiaquine and 4-aminoquinolones resistance in P. vivax16. 
Resistance in P.  vivax against SP has been associated 
with mutations in dihydrofolate reductase (pvdhfr) and 
dihydropteroate synthetase (pvdhps) genes. Pvdhfr mutations 
I13L, P33L, F57L/I, S58R, T61M, S117N/T, I173L/F, and 
pvdhps mutations S382A/C, A383G, K512M/T/E, and 
A553G/C genes have been linked to reduced susceptibility 
to pyrimethamine and sulfadoxine, respectively17.
In Pakistan, previous molecular antimalarial surveillance 
studies focused on different regions of Pakistan and 
FATA were neglected due to military operations and the 
war against terrorism. In this study, molecular markers 
associated with antimalarial drug resistance were 
investigated in P. falciparum and P. vivax clinical isolates 
collected from five FATA agencies/districts. Samples 
collected in 2017-2018 provided information regarding the 
prevalence of antimalarial resistant genotypes in the two 
predominant Plasmodium species: P.  falciparum (pfdhfr, 
pfdhps, pfcrt, and pfmdr1) and P.  vivax (pvdhfr, pvdhps 
and pvmdr1). The study findings will contribute to a better 
understanding on the patterns of molecular drug resistance 
markers in P. falciparum/vivax in this region.
MATERIALS AND METHODS
Study site and patient enrollment
This study was carried out in the FATA agency, and in 
May 2018, this region was merged with the KPK province. 
FATA has unique geographical importance as it shares its 
border with Afghanistan to the West, KPK to the Northeast, 
and Balochistan to the South. It is located at latitude 
34° 28’ 24.59” North and Longitude 71° 17’ 16.20” East, 
stretching for a maximum length of about 450 kilometers. 
Blood samples from malaria suspect cases were collected by 
the basic health units and different private health units from 
five agencies/districts (Bajaur, Mohmand, Khyber, Orakzai, 
and Kurram Agency) of FATA (Figure 1), KPK between May 
2017 to May 2018. After explaining the study’s purpose, 
informed verbal consent was taken from all patients or their 
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legal guardians in the case of patients under the age of 18. 
The verbal consent was taken because it is a war-affected 
area, and the study population was mainly illiterate and the 
study would be of minimal risk to the study participants. All 
the questions raised by the participants were answered, and 
they were given time to decide if they wanted to participate. 
This consenting process was applied in the presence of 
an impartial witness. Ethical approval for this study was 
obtained from the ethical committee of the Department of 
Biochemistry & Biotechnology, University of Gujrat, Gujrat, 
Punjab, Pakistan. 
Laboratory methodology
A total of 762 malaria-positive blood samples, diagnosed 
by microscopy, were collected regardless of age and gender. 
About 3 mL of peripheral blood were drawn in EDTA tubes, 
and 50 µL of whole blood were spotted on Whatman filter 
paper, dried, and stored at room temperature, and EDTA 
blood samples were stored at -80 °C. Malarial DNA was 
extracted from the dried blood spots using the QIAmp 96 
DNA kit (Qiagen, Valencia, CA, USA) according to the 
manufacturer’s instructions. 
Plasmodium DNA amplification by nested PCR 
Nested PCR was used to genotype the 18S rRNA 
Plasmodium gene with genus-specific and species-specific 
primers (P. falciparum, P. vivax, P. malariae and P. ovale) 
as previously described18. In addition, the PCR master mix, 
primer sequences, and thermal cycler conditions followed 
previously used protocols19. Nested PCR amplification 
products were electrophoresed on 2% agarose gels, 
along with a molecular ladder (Thermo Fisher Scientific, 
Waltham, MA, USA). 
PCR amplification for pyrosequencing (pfdhfr, pfdhps, 
pfcrt, and pfmdr1) 
Screening for polymorphism linked to anti-folate 
resistance, present at codons 50, 51, 59, 108 164 of the 
pfdhfr gene and 436, 437, 540,581, 613 of the pfdhps 
gene in P. falciparum was performed by pyrosequencing 
using primers from a previously reported protocol20. The 
CQR molecular marker pfcrt codon K76T containing the 
gene fragment and N86Y and Y184F of the pfmdr1 gene 
were amplified using the Khattak et al.11 protocol. PCR 
reagents and thermal cycler conditions were adopted from 
a previously described protocol with slight modifications. 
Briefly, in primary PCR reaction, 25 µL reaction volume 
was used having 2 μL of template DNA, 2x PCR buffer, 
0.2  mM dNTPs, 1.0 mM magnesium chloride, 0.4 µM 
primer (forward and reverse), and 0.04 U/µL Taq DNA 
polymerase (Promega, Madison, WI, USA). Then, about 
2 µL of the first PCR product were used as the template 
DNA for the nested PCR, 1× PCR buffer, 0.3 mM dNTPs, 
Figure 1 - Geographical map of Pakistan indicating the provinces and the FATA region.
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1.0 mM magnesium chloride, 0.4 µM both primers, and 
0.04 U/µL Taq DNA polymerase, in a total volume of 50 μL. 
Primers and thermal cycler conditions followed previous 
protocols11,12. PCR was performed using a BioRad thermal 
cycler (Bio-Rad Laboratories, Hercules, CA, USA), and 
the amplification products were visualized on 2% ethidium 
bromide-stained agarose gels under UV lights. All samples 
were processed for pyrosequencing at the University of 
Maryland, School of Medicine facility in Baltimore, USA.
Pyrosequencing reaction
To investigate the mutations present at all codons of 
interest, pyrosequencing was carried on PyroMark® Q96 
MD Pyrosequencer (Qiagen, Valencia, CA, USA) using a 
published protocol20. Depending on the intensity/quantity 
of the amplification product, 3 to 6 μL of the second PCR 
product or control samples (wild and mutant samples for 
each codon) were used in each pyrosequencing reaction. 
PyroMark® software of Pyrosequencer Q96 MD version 1.2 
Qiagen (Biotage AB, Uppsala, Sweden) was used to achieve 
an allele quantification mode (AQ) for all SNPs. However, 
pfcrt (codons 72–76) and pfmdr1 (codons N86Y and 
Y184F) were analyzed using the sequence analysis mode 
(SQA). After adjusting each allele cut-off value against 
the control DNA using a standard curve, allele frequencies 
greater than 10% were considered.
Sequencing of P. vivax genes (pvdhps, pvdhfr, and 
pvmdr1) 
A subset of 75 P.  vivax samples from five FATA 
agencies/districts (study sites) were amplified targeting 
pvdhps (767 bp), pvdhfr (632 bp), and pvmdr1 (547 bp) 
genes harboring mutations associated with CQR and SP 
resistance. Using previously described PCR master mix 
reagents protocols and cycling conditions, the first and 
second amplifications were carried out to amplify pvdhps, 
pvdhfr, and pvmdr1 genes of P. vivax using blood samples 
and control samples (positive and negative)21. The first 
and second round PCRs master mix concentrations and 
thermal cycler conditions were the same for all three genes. 
Purified DNA samples were sent to the Sanger Sequencing 
Service at Macrogen Korea. All electropherograms were 
first visualized, then assembled, and finally analyzed by the 
Sequencher 4.1.10 (Gene Codes Corporation, Ann Arbor, 
MI, USA). Wild type genes P. vivax ARI/Pakistan isolated 
(GenBank accession Nº X98123), Sal-1 strain (GenBank 
accession no AY618622), and a Brazilian clinical isolate 
(GenBank accession Nº AY186730) were used for pvdhfr, 
pvdhps, and pvmdr1 genes as reference sequences. 
RESULTS 
Out of 762 malaria- positive blood samples by 
microscopy, 679 samples were positive for Plasmodium 
DNA by PCR. From this total of samples, 523 (77%) 
were positive for P.  vivax, 121 (18%) were positive for 
P.  falciparum, and 35 (5%) were found to harbor mixed 
infections. Among patients who tested positive for PCR, 
468 (68%) were male, and 211 (32%) were female; the male 
to female ratio was 2.21. The patients’ ages ranged from 
6 months to 70 years, with a median of 22 years.
Polymorphisms in pfdhfr, pfdhps, pfmdr1 and pfcrt 
genes of Plasmodium falciparum
Pyrosequencing was used to detect SNPs in the pfdhfr, 
pfdhps, pfmdr1 and pfcrt genes in 156 malaria-positive, 
PCR-confirmed isolates [121 P. falciparum mono-infections 
and 35 infections with mixed species (P.  falciparum 
plus P.  vivax)]. All blood samples harbored C59R and 
S108N mutations; consequently, pfdhfr double mutants 
(C59R  +  S108N) were 156/156 (100%), indicating a 
complete predominance of this haplotype in the study 
population. No mutation was observed at position I164L of 
the pfdhfr gene. However, the double mutant C50R + N51I 
was found in 17/156 (10.9%) of the isolates, and no triple 
pfdhfr (N51I + C59R + S108N) mutant was observed. In 
the pfdhps gene, S436A/F and A437G mutations were 
found in 16/156 (10.3%) and 24/156 (15.1%) of the 
isolates. All P. falciparum blood samples were wild-type 
at codon K540E, A581G and A613T/S. The prevalence of 
a combination of triple dhfr/dhps (C59R+S108N+A437G) 
mutant was 18/156 (11.5%) (Table 1). Pfmdr1 polymorphism 
data showed that the frequency of N86Y and Y184F was 
29/156 (18.2%) and 16/156 (10.2%), respectively. The 
Table 1 - Frequency of genotype at various sites and SNPs in 
Plasmodium falciparum pfdhfr, pfdhps, pfmdr1 and pfcrt genes. 
Number of samples = 156. 
Gene Mutation/Haplotype Samples No. (%)
pfdhfr C59R 156 (100)
S108N 156 (100)
C50R+ N51I 17 (10.9)
C59R + S108N 156 (100)
pfdhps S436A/F 15 (10)
A437G 24 (15)
pfdhfr + pfdhps 59R + 108N + 437G 18 (11.5)
pfmdr1 N86Y 29 (18.6)
 Y184F 16 (10.3)
pfcrt K76T 152 (97.4)
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Polymorphism analysis of the pfcrt gene fragment showed 
152/156 (97.4%) K76T mutations.
Polymorphisms in Plasmodium vivax pvdhfr, pvdhps 
and pvmdr1 genes 
Amplification and sequencing of the pvdhfr gene 
revealed that about 27/75 (36.2%) of P.  vivax isolates 
harbored the S117N mutation while the incidence of the 
S58R single mutant was about 19/75 (25%). A double 
pvdhfr (S58R+S117N) mutant was observed in 17/71 
(23.9%) of P. vivax blood samples (Table 2). Concerning 
the pvdhfr wild type gene sequence (P. vivax ARI/Pakistan 
isolate GenBank accession no: X98123), the 18-bp double 
insertions (insertion I and II) and one 18 bp deletion were 
observed. Insertion I was located between the 91-92 codons, 
insertion II was between 102-104 codons, and deletions 
were between 92-97 codons after local alignment with the 
wild type pvdhfr gene sequence. The tandem repeat region 
of the P. vivax pvdhfr gene was aligned between amino acids 
84 and 106 (Figure 2). Insertion II was the most common, 
accounting for 8/75 (10.6%), followed by deletions, which 
were observed in 5/75 (6.6%) isolates, and insertion I was 
observed in 3/75 (4%) isolates.
The majority of samples sequenced to investigate point 
mutations associated with the sulphadoxine resistant gene 
(pvdhps) were wild-type reference sequences (Brazilian 
clinical isolate accession no: AY186730). Only 2.1% of 
samples carrying the A383G mutation; however, none 
of the isolates presented with mutations at codon A553G 
in the pvdhps gene. The incidence of pvdhfr + pvdhps 
double mutants (S117N+A383G) was observed in 1.7% of 
specimens collected from the FATA region. 
P. vivax CQR-associated mutations, Y976 and F1076, 
were screened after sequencing the pvmdr1 gene region 
between codons 931 and 1095 (Reference Sal-1 Gen-Bank 
accession Nº AY618622). The amplified gene fragments 
indicated 98.9% of mutations at codons F1076L and only 
1.1% of samples harboring the Y976F mutation. 
DISCUSSION
Malaria infection, the country’s second most commonly 
reported disease, affects 205 million Pakistani. Molecular 
analysis of SP resistance-associated marker gene (pfdhfr) 
in P.  falciparum showed 100% prevalence of the double 
pfdhfr (C59R/S108N) mutant, indicating a complete 
predominance of this haplotype. Two previous studies from 
the FATA region reported 96% and 97.6% prevalence of the 
double pfdhfr mutant12,22. In addition, a high incidence of 
the pfdhfr double mutant has also been reported in different 
Pakistan cities12,13. 
In the present study, the A437G mutation was observed 
in 15% of the isolates. Similar results were obtained 
when samples collected from the FATA Khyber Agency, 
reporting a 10.9% prevalence of the A437G mutation12. In 
this study, 12% of P. falciparum isolates harbored pfdhfr 
+ pfdhps triple (C59R + S108N and A437G) mutation. A 
survey conducted in the FATA region has reported a 9.8% 
prevalence of triple mutants, and it was comparatively 
lower than in the Balochistan province (83.3%)12. A study 
published in 2013 reported a 51% prevalence of pfdhfr+ 
Table 2 - Frequency of genotype at various sites and SNPs in 
Plasmodium vivax pvdhfr, pvdhps and pvmdr1 genes. Number 
of samples = 75. 
Gene Haplotype
No. samples and 
(percentage)
pvdhfr IPFSTN I 27 (36)
 IPFR TN I 19 (25.3)
pvdhps SAKAV (WT) 73 (97.3)
SG KAV 2 (2.1)
pvdhfr + pvdhps IPFSTSISAKAV (WT) 29 (38.7)
IPFSTN ISAKAV 26 (35.5)
IPFR TN ISAKAV 17 (23.8)
IPFSTN ISG KAV 1 (1.7)
pvmdr1 YF (WT) 1 (1.1)
YL 75 (98.9)
Pvdhfr = wild type haplotype (IPFSTSI) I13L, P33L, F57L/I, 
S58R, T61M, S117N/T and I173L/F; Pvdhps = wild type 
haplotype (SAKAV) S382, A383, K512, A553 and V585; pvmdr1 
= wild type haplotype (YF) Y976F and F1076L.
Figure 2 - Alignment of P. vivax pvdhfr gene sequences, focusing the tandem repeat region between amino acids 84 and 106. The 
pink color indicates the tandem repeat, and the asterisk (*) in green colored boxes represent the tandem repeat deletion between 
positions 98 and 103. 
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pfdhps triple mutation in all four Pakistan provinces, but 
samples from FATA were not included11. The decrease 
in the incidence of the pfdhfr  + pfdhps triple mutant 
haplotype was also observed in Iran, decreasingfrom 53% 
to 38% between 2008 and 2010 after exchanging CQ and 
SP monotherapy for AS+SP23. No polymorphism was 
observed in pfdhps, codons K540E, A581G, and A613S/T 
while a study reported 4% and 3% of polymorphisms at 
K540E and A581G codons in Pakistan21. The highly-
resistant quintuple mutant [combination of the pfdhfr triple 
mutant (51I+59R+108N) and the pfdhps double mutant 
(437G+540E)] associated with SP treatment failure24 was 
not reported in this study or in earlier reports from the 
FATA region in Pakistan12.
Analysis of mutations in the pfmdr1 gene showed that 
18% of isolates had a mutation at codon N86Y, and 10% 
of isolates were mutated at codon Y184F; this findings 
contrasts with the ones from studies from Pakistan in which 
25% of samples included mixed mutations (if both the wild-
type and mutant alleles were detected)11. In Asia and Africa, 
the association of CQR with the N86Y codon mutation is 
not clear. There are still gaps to increase the understanding 
on the association of SNPs in pfmdr1 gene with CQR25. 
Our results showed that P. falciparum CQ resistant K76T 
pfcrt mutation has completely predominated or is near the 
100% frequency as this mutation was observed in 97% of 
isolates collected by five FATA agencies. In 2009, a study 
of samples gathered from the Bannu area, which is near 
the FATA zone, found that 100% of samples had the pfcrt 
K76T mutation13. Similarly, a study conducted in Pakistan 
in 2013 found the same results8. A survey of clinical isolates 
collected from all over Pakistan in 2018 found that 98.3% 
of the country had the CQR15, and comparable results have 
been reported from adjacent countries26. 
In P. vivax samples, the S117N (IPFSTNI single mutant) 
pvdhfr haplotype was found in 36% of the samples in this 
study, and a survey from Pakistan in 2013 reported a 45% 
prevalence of this haplotype21. In contrast, another study 
from Bannu reported about 93% prevalence13. Quadruple 
57L/58R/61M/117T, triple 57L/58R/117 and double pvdhfr 
(57L/117N) mutant haplotypes have been associated with 
in vitro drug resistance16. This study found pvdhfr double 
mutant S58R + S117N in 25% of clinical isolates reported 
from neighboring countries like India, Afghanistan and 
Iran27-29. 
In this study, two insertions (I and II) and one deletion 
of 18 base pairs have been observed. These nucleotides 
insertion/deletion events in the pvdhfr known repeated 
regions, as well as their roles, warrant more investigation. 
A study conducted in Southern Pakistan has also reported 
insertions/deletions in the pvdhps gene30. Many studies have 
used these repeated regions to study pvdhfr and pvdhps 
alleles based on their genetic diversity31,32. An apparent 
association of tandem repeat variants with mutant alleles 
and disease severity has been proposed33. According to the 
studies, these tandem repeat variants could be employed in 
genotyping analyses of dhfr and dhps alleles31,34. 
P.  vivax can be exposed to SP pressure (alone or in 
combination with artesunate) in an effect possibly involved 
in misdiagnosis, as mixed infections are frequently treated 
with SP or AS-SP. 
Presumptive diagnosis is relatively high in Pakistan, 
especially in FATA where medical facilities are not 
adequate. However in some patients, P. vivax parasites are 
exposed to SP pressure at sub-therapeutic levels, which 
can favor the emergence of resistance to SP4. However, 
it seems that despite some use of SP or AS-SP, P. vivax 
isolates carrying the mutant pvdhfr-pvdhps have not been 
selected to a large extent. 
The majority (97.9%) of P.  vivax isolates had the 
wild-type pvdhps haplotype (SAKAV), and only 2.1% of 
isolates had the mutant SGKAV haplotype; these findings 
are in line with a previous study21. The low prevalence of 
this pvdhps mutant haplotype SAKAV has been reported in 
Iran and Afghanistan35,36. The haplotype analysis revealed 
that IPFSTNI + SGKAV (pvdhfr + pvdhps) mutations are 
rare in the FATA region as these mutations are significantly 
associated with extensive drug resistance revealed by the 
molecular marker. Our study found four mutations in 
pvdhps, namely F365L, M367L, D459Aand V498A, and 
out of these four mutations, two mutations, F365L, M367L, 
have been reportedin India33.
In the present study, only 1% of isolates had point 
mutation at codon Y976F, but 7% of mutations at this 
position Y976F have been reported in India37. Our findings 
are consistent with two other studies from neighboring 
countries that reported CQ susceptibility, but the mutant 
Y976F was not observed in these two studies38,39. The 
F1076L mutation in the pvmdr1 gene of P. vivax isolates 
was highly predominant (99%) in all FATA study sites 
which showas a nearly complete predominance. Our 
findings are in line with previous reports from Pakistan, 
in which about 98% of mutations have been reported at 
position F1076L. Nearly all isolates were wild-type at the 
Y796F position, suggesting that CQ resistance in P. vivax 
has not yet emerged, but many isolates carried the F1076L 
mutant13,21. Our study found the F1076L mutation in all 
samples compared to the reference wild type sequence, but 
few studies reported that this mutation alone could be non 
associated with CQ resistance. 
In order to express CQR in P.  vivax isolates, both 
mutations must be present, however there is no evidence 
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that the Y976F mutation represents a molecular marker for 
CQ resistance40. 
CONCLUSION
This is the first comprehensive report on molecular 
genotyping and molecular patterns of drug resistance 
markers in P.  falciparum and P.  vivax isolates in FATA 
regions of Pakistan. Drug resistance findings suggest 
that although there is a high prevalence of pfdhfr double 
mutations in P.  falciparum isolates across all FATA 
regions, these mutations are insufficient to transmit SP 
failure in clinical settings. In addition, a high prevalence 
of P. falciparum CQR markers has been found despite the 
discontinuation of drug pressure. 
In P. vivax isolates, no primary chloroquine resistance-
mediating mutation was found; however, a continuous 
monitoring of pvmdr1 mutations is essential to identify the 
emergence of CQ resistant P. vivax in the FATA regions. 
Furthermore, the utility of parasite molecular markers 
to monitor drug resistance significantly impacts malaria 
control and elimination in the war-torn malaria endemic 
area, FATA. Therefore, to better understand malaria 
transmission, continuous molecular studies to determine 
genetic diversity are recommended.
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